Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy

被引:128
作者
Awad, AS
Huang, LP
Ye, H
Duong, ETA
Bolton, WK
Linden, J
Okusa, MD
机构
[1] Univ Virginia, Dept Med, Charlottesville, VA USA
[2] Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA USA
关键词
proteinuria; diabetes; macrophage; kidney; ATL146e;
D O I
10.1152/ajprenal.00310.2005
中图分类号
Q4 [生理学];
学科分类号
071003 [生理学];
摘要
We previously demonstrated the anti-inflammatory effects and renal tissue protection in response to adenosine A(2A)-receptor ( A(2A)R) activation in acute renal injury. We sought to extend these studies and determine the efficacy of A(2A)R agonists in a chronic model of renal injury. We hypothesized that A(2A) agonists mediate renal tissue protection in diabetic nephropathy by reducing glomerular inflammation. Diabetes was induced with single intravenous injection of streptozotocin in Sprague-Dawley rats ( 50 mg/kg). Increases in urinary albumin excretion ( UAE) and plasma creatinine at week 6 in the diabetes group ( 26- and 6-fold over control, respectively) were markedly reduced by continuous subcutaneous administration of ATL146e ( 10 ng.kg(-1).min(-1)), a selective A(2A) agonist. The increase in UAE in the diabetes group was associated with a significant reduction in the expression of slit diaphragm-associated molecules compared with control ( nephrin; P < 0.05 and podocin; P < 0.005) that was reversed by ATL146e treatment. Diabetes led to an increase in urinary excretion of monocyte chemoattractant protein-1 ( 705% of control), TNF-alpha ( 1,586% of control), IFN-gamma ( 298% of control), kidney fibronectin mRNA ( 457% of control), and glomerular infiltration of macrophages ( 764% of control), effects significantly reduced by ATL146e treatment. Mesangial expansion and basement membrane thickness were reduced with ATL146e. To further confirm the selectivity of ATL146e, we used wild-type ( WT) or A(2A) knockout ( A(2A)-KO) mice. Four weeks after diabetes, UAE increased significantly in both WT and A(2A)-KO diabetic mice ( 3.0- and 3.3-fold over control). A(2A) agonist treatment blocked the increase in UAE in WT diabetic mice ( P < 0.001), whereas it had no effect on the A(2A)-KO diabetic mice. These results demonstrate that chronic A(2A)R activation in diabetic rats 1) ameliorates histological and functional changes in kidneys induced by diabetes and 2) causes reduced inflammation associated with diabetic nephropathy.
引用
收藏
页码:F828 / F837
页数:10
相关论文
共 56 条
[1]
American Diabetes Association, 2001, DIABETES CARE S1, V24, pS69
[2]
[Anonymous], 2000, The Kidney
[3]
Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy [J].
Banba, N ;
Nakamura, T ;
Matsumura, M ;
Kuroda, H ;
Hattori, Y ;
Kasai, K .
KIDNEY INTERNATIONAL, 2000, 58 (02) :684-690
[4]
PRODUCTION OF TUMOR NECROSIS FACTOR BY RAT MESANGIAL CELLS IN RESPONSE TO BACTERIAL LIPOPOLYSACCHARIDE [J].
BAUD, L ;
OUDINET, JP ;
BENS, M ;
NOE, L ;
PERALDI, MN ;
RONDEAU, E ;
ETIENNE, J ;
ARDAILLOU, R .
KIDNEY INTERNATIONAL, 1989, 35 (05) :1111-1118
[5]
Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy [J].
Benigni, A ;
Gagliardini, E ;
Tomasoni, S ;
Abbate, M ;
Ruggenenti, P ;
Kalluri, R ;
Remuzzi, G .
KIDNEY INTERNATIONAL, 2004, 65 (06) :2193-2200
[6]
Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat [J].
Benigni, A ;
Zoja, C ;
Corna, D ;
Zatelli, C ;
Conti, S ;
Campana, M ;
Gagliardini, E ;
Rottoli, D ;
Zanchi, C ;
Abbate, M ;
Ledbetter, S ;
Remuzzi, G .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1816-1824
[7]
Bonnet F, 2001, DIABETOLOGIA, V44, P874
[8]
BORDER WA, 1994, NEW ENGL J MED, V331, P1286
[9]
Decreased cardiac output at the onset of diabetes: renal mechanisms and peripheral vasoconstriction [J].
Brands, MW ;
Fitzgerald, SM ;
Hewitt, WH ;
Hailman, AE .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2000, 278 (05) :E917-E924
[10]
Poor glycemic control induces hypertension in diabetes mellitus [J].
Brands, MW ;
Hopkins, TE .
HYPERTENSION, 1996, 27 (03) :735-739